WuXi PharmaTech and ShangPharma Are M&A Targets: Bloomberg

WuXi PharmaTech and ShangPharma are both attractive M&A targets, according to a Bloomberg News article. Both China CROs have higher profit margins than their US peers, and both are growing faster than US CROs. Nevertheless, their PE ratios are lower, making them value propositions for their US competitors. To gain perspective on the situation, Bloomberg quoted Greg Scott, ChinaBio®’s CEO, who said China’s CRO industry is healthy, with demand growing steadily. Both companies have the “ability to deliver a cost advantage while maintaining very high quality,” he added. More details.... Stock Symbol: (NYSE: WX) (NYSE: SHP) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});